<DOC>
	<DOCNO>NCT00477737</DOCNO>
	<brief_summary>In vitro study vivo animal experiment show halogenated volatile anesthetic protective effect ischemic myocardium . In clinical setting however , anesthetic preconditioning may interest . The aim study evaluate cardioprotective effect sevoflurane patient undergo off-pump coronary artery bypass surgery . We propose cardioprotective effect sevoflurane would save myocardial function , measure acceleration esophageal Doppler cardiac index bolus thermodilution method , brief ischemia reperfusion .</brief_summary>
	<brief_title>Early Cardioprotective Effect Sevoflurane</brief_title>
	<detailed_description>Studies perform human patient undergo CABG surgery cardiopulmonary bypass ( CPB ) . Only study however evaluate effect volatile anesthetic coronary artery bypass graft beat heart ( OPCABG ) conflict result far cardiac biomarker release concern . Because CPB know profound impact cardiac function , study perform patient schedule OPCABG could evaluate specifically effect anesthetic agent . Patients undergo OPCABG predictable predefined ischemic zone surgery represent extremely interesting safe model study ischemia cardiac damage human . Presently , still consensus method administration volatile anesthetic , include time begin administration , duration , dosage selection volatile anesthetic .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>degree I II Cardiac Anesthesia Risk Evaluation score angiographically verify coronary artery disease leave ventricular ejection fraction high 40 % atrioventricular conduction disturbance previously ventricular arrhythmia require antiarrhythmic treatment atrial fibrillation rapid ventricular response myocardial infarction stroke within 6 month diabetes mellitus endstage obstructive restrictive pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>cardioprotection</keyword>
	<keyword>sevoflurane</keyword>
	<keyword>esophageal Doppler</keyword>
	<keyword>thermodilution</keyword>
	<keyword>coronary artery bypass</keyword>
</DOC>